The estimated Net Worth of Christina Willwerth is at least $1.4 Milión dollars as of 19 July 2021. Ms. Willwerth owns over 3,945 units of Flexion Therapeutics Inc stock worth over $1,298,005 and over the last 6 years she sold FLXN stock worth over $98,926. In addition, she makes $0 as Chief Strategy Officer at Flexion Therapeutics Inc.
Sign up
Ms. Willwerth FLXN stock SEC Form 4 insiders trading
Christina has made over 4 trades of the Flexion Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 3,945 units of FLXN stock worth $25,445 on 19 July 2021.
The largest trade she's ever made was exercising 8,750 units of Flexion Therapeutics Inc stock on 13 August 2019 worth over $1,400. On average, Christina trades about 2,075 units every 64 days since 2019. As of 19 July 2021 she still owns at least 141,241 units of Flexion Therapeutics Inc stock.
You can see the complete history of Ms. Willwerth stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christina Willwerth biography
Christina Willwerth serves as Chief Strategy Officer of the Company. Ms. Willwerth was named our Chief Strategy Officer in January 2019. Ms. Willwerth joined Flexion in June 2009, and she most recently served as the Company’s Senior Vice President of Program Management and Strategy. Ms. Willwerth joined Flexion from ViaCell, Inc., where she was a member of the company’s Executive Management team and served as Vice President, Product Development, with management responsibility for the company’s interdisciplinary cellular therapy and fertility preservation development programs. She previously served as Senior Director, Product Development at The Medicines Company, where she focused on cardiovascular therapy clinical and product development. Prior to that, she held a number of ascendant clinical operations positions at Astra Pharmaceuticals and Biopure Corporation. Ms. Willwerth holds a BS in Biology, with high distinction, from Worcester Polytechnic Institute.
How old is Christina Willwerth?
Christina Willwerth is 49, she's been the Chief Strategy Officer of Flexion Therapeutics Inc since 2019. There are 14 older and 2 younger executives at Flexion Therapeutics Inc. The oldest executive at Flexion Therapeutics Inc is Samuel Colella, 80, who is the Independent Director.
What's Christina Willwerth's mailing address?
Christina's mailing address filed with the SEC is C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON, MA, 01803.
Insiders trading at Flexion Therapeutics Inc
Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon a Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.
What does Flexion Therapeutics Inc do?
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.
What does Flexion Therapeutics Inc's logo look like?
Complete history of Ms. Willwerth stock trades at Flexion Therapeutics Inc
Flexion Therapeutics Inc executives and stock owners
Flexion Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Michael Clayman,
President, Chief Executive Officer, Director -
David Arkowitz,
Chief Financial Officer -
Scott Kelley,
Chief Medical Officer -
Mark Levine,
General Counsel and Corporate Secretary -
Dr. Neil Bodick,
Consultant -
Patrick Mahaffy,
Independent Chairman of the Board -
Sandesh Mahatme,
Independent Director -
Samuel Colella,
Independent Director -
Alan Milinazzo,
Independent Director -
Mark Stejbach,
Independent Director -
C. Ann Merrifield,
Independent Director -
Scott Canute,
Independent Director -
Heath Lukatch,
Independent Director -
Scott Young,
IR Contact Officer -
Elizabeth Kwo,
Director -
Christina Willwerth,
Chief Strategy Officer -
Kerry Wentworth,
Chief Regulatory Officer -
Melissa Layman,
Chief Commercial Officer -
John Magee,
VP of Sales -
Carolyn Beaty Scimemi,
VP, Legal Affairs & Chief Compliance Officer -
David A. Arkowitz M.B.A.,
Chief Financial Officer -
Ventures Iii, Llc Versant V...,
-
Yamo Deniz,
Chief Medical Officer -
Frederick W Driscoll,
Chief Financial Officer -
Barbara N Bolzon Bradley J ...,
-
William T. Andrews,
Chief Medical Officer -
Utpal Koppikar,
Director -
Neil Bodick,
Chief Scientific Officer -
Ventures Ii Lp5 Am Co Inves...,
-
Holdings A/S Novo,
10% owner -
Partners Sas Sofinnova,
10% owner -
Venture Capital Iii, L.P.Bo...,
-
Venture Capital Iii, L.P.Ve...,
-
Rafael Tordjman,
Director -
Andrew J. Schwab,
Director -
Bradley J Ph D Bolzon,
Director -
Venture Capital Iii, L.P.Ve...,
-
Inc Pfizer,
10% owner -
Management, Llc Newtyn,
10% owner -
Adam Muzikant,
Chief Business Officer